Meeting
2019 Gastrointestinal Cancers Symposium
Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX/FOLFIRI plus cetuximab.
Authors
S.P. Somashekhar
Manipal Comprehensive Cancer Center, Bangalore, India
S.P. Somashekhar , Amit Rauthan , Ashwin K Rajgopal , Rohit Kumar C
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 631)
DOI
10.1200/JCO.2019.37.4_suppl.631
Abstract #
631
Poster Bd #
K16
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Predictive factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer.
First Author: AhReum Lim
Poster
2017 Gastrointestinal Cancers Symposium
A phase II study of panitumumab with FOLFOX or FOLFIRI as first-line chemotherapy for KRAS-wild type metastatic colorectal cancer: The PaFF-J study.
First Author: Eiji Shinozaki
Poster
2017 Gastrointestinal Cancers Symposium
CEA response and depth of response (DpR) to predict clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line cetuximab plus oxaliplatin-based chemotherapy: A sub-analysis of the JACCRO CC-05/06 trials.
First Author: Yu Sunakawa
Poster
2016 Gastrointestinal Cancers Symposium
Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab.
First Author: Stefano Cascinu